Evans syndrome natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 11: Line 11:
==Prognosis==
==Prognosis==
* The [[prognosis]] depends on the patient’s response to treatment. Spontaneous remissions of each of the individual component conditions have been reported. If the child responds well to the treatment and the levels of [[platelets]] and [[red blood cells]] increase, the child can expect to live a normal life. Medications will be needed life long, and laboratory tests will need to be constantly monitored to detect any abnormal changes so that treatment can be adjusted.  
* The [[prognosis]] depends on the patient’s response to treatment. Spontaneous remissions of each of the individual component conditions have been reported. If the child responds well to the treatment and the levels of [[platelets]] and [[red blood cells]] increase, the child can expect to live a normal life. Medications will be needed life long, and laboratory tests will need to be constantly monitored to detect any abnormal changes so that treatment can be adjusted.  
* In more serious cases Evans syndrome can massively reduce life span and is seriously life threatening.  
* In more serious cases Evans syndrome can reduce life span and may be seriously life threatening.  
* Evan's Syndrome is rare and has a reported [[mortality rate]] of just under 18%.
* Evan's Syndrome is rare and has a reported [[mortality rate]] of just under 18%.
* It has been observed that there is a risk of developing other autoimmune problems and [[hypogammaglobulinemia]],<ref name="pmid3071168">{{cite journal |author=Wang WC |title=Evans syndrome in childhood: pathophysiology, clinical course, and treatment |journal=The American journal of pediatric hematology/oncology |volume=10 |issue=4 |pages=330–8 |year=1988 |pmid=3071168 |doi=10.1097/00043426-198824000-00013}}</ref> with recent research finding that 58% of children with Evans syndrome have CD4-/CD8- [[T cells]] which is a strong predictor for having [[autoimmune lymphoproliferative syndrome]].<ref name="pmid15542578">{{cite journal |author=Teachey DT |title=Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS) |journal=Blood |volume=105 |issue=6 |pages=2443–8 |year=2005 |pmid=15542578 |doi=10.1182/blood-2004-09-3542 |url=http://bloodjournal.hematologylibrary.org/cgi/content/full/105/6/2443 |author2=Manno CS |author3=Axsom KM |display-authors=3 |last4=Andrews |first4=T |last5=Choi |first5=JK |last6=Greenbaum |first6=BH |last7=McMann |first7=JM |last8=Sullivan |first8=KE |last9=Travis |first9=SF}}</ref>
* It has been observed that there is a risk of developing other autoimmune problems and [[hypogammaglobulinemia]],<ref name="pmid3071168">{{cite journal |author=Wang WC |title=Evans syndrome in childhood: pathophysiology, clinical course, and treatment |journal=The American journal of pediatric hematology/oncology |volume=10 |issue=4 |pages=330–8 |year=1988 |pmid=3071168 |doi=10.1097/00043426-198824000-00013}}</ref> with recent research finding that 58% of children with Evans syndrome have CD4-/CD8- [[T cells]] which is a strong predictor for having [[autoimmune lymphoproliferative syndrome]].<ref name="pmid15542578">{{cite journal |author=Teachey DT |title=Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS) |journal=Blood |volume=105 |issue=6 |pages=2443–8 |year=2005 |pmid=15542578 |doi=10.1182/blood-2004-09-3542 |url=http://bloodjournal.hematologylibrary.org/cgi/content/full/105/6/2443 |author2=Manno CS |author3=Axsom KM |display-authors=3 |last4=Andrews |first4=T |last5=Choi |first5=JK |last6=Greenbaum |first6=BH |last7=McMann |first7=JM |last8=Sullivan |first8=KE |last9=Travis |first9=SF}}</ref>
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 17:04, 2 February 2016

Evans syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Evans syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Evans syndrome natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Evans syndrome natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Evans syndrome natural history, complications and prognosis

CDC on Evans syndrome natural history, complications and prognosis

Evans syndrome natural history, complications and prognosis in the news

Blogs on Evans syndrome natural history, complications and prognosis

Directions to Hospitals Treating Evans syndrome

Risk calculators and risk factors for Evans syndrome natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2] Ammu Susheela, M.D. [3]

Overview

If left untreated, patients with Evans syndrome have periods of exacerbation. Common complications of Evans syndrome include thrombocytopenia and autoimmune haemolytic anaemia. Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good.

Natural History

  • The disease has a chronic course with periods of exacerbation and remissions. The remissions are induced by treatment.

Complications

Prognosis

  • The prognosis depends on the patient’s response to treatment. Spontaneous remissions of each of the individual component conditions have been reported. If the child responds well to the treatment and the levels of platelets and red blood cells increase, the child can expect to live a normal life. Medications will be needed life long, and laboratory tests will need to be constantly monitored to detect any abnormal changes so that treatment can be adjusted.
  • In more serious cases Evans syndrome can reduce life span and may be seriously life threatening.
  • Evan's Syndrome is rare and has a reported mortality rate of just under 18%.
  • It has been observed that there is a risk of developing other autoimmune problems and hypogammaglobulinemia,[1] with recent research finding that 58% of children with Evans syndrome have CD4-/CD8- T cells which is a strong predictor for having autoimmune lymphoproliferative syndrome.[2]

References

  1. Wang WC (1988). "Evans syndrome in childhood: pathophysiology, clinical course, and treatment". The American journal of pediatric hematology/oncology. 10 (4): 330–8. doi:10.1097/00043426-198824000-00013. PMID 3071168.
  2. Teachey DT; Manno CS; Axsom KM; et al. (2005). "Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS)". Blood. 105 (6): 2443–8. doi:10.1182/blood-2004-09-3542. PMID 15542578.